Abstract 203P
Background
Esophageal squamous cell carcinoma (ESCC) is the main subtype of esophageal cancer in China. We conducted a prospective clinical trial of preoperative Durvalumab combined chemotherapy in patients with locally advanced ESCC.
Methods
Clinical resectable IIB-IVA ESCC patients were enrolled in the study. Patient received neoadjuvant Durvalumab 750mg combined chemotherapy (docetaxel 75mg/m2 plus cisplatin 75mg/m2 or carboplatin area under curve 4-5) every 3 weeks for 4 cycles before surgery. The primary endpoint was the pathological complete response rate (pCR) and the radical resection rate (R0).
Results
26 eligible patients were enrolled in the study and all completed four cycles of neoadjuvant therapy. The objective response rate is 80.8%, and the disease control rate was 100%. Among the 22 resectable tumor patients, 20 received McKeown MIE, and the other 2 patients who achieved response (1 PR and 1 CR) refused surgery due to concerns about complications. 20 patients underwent esophagectomy within 33-60 days (median 47 days) after neoadjuvant therapy, and 19 patients underwent radical resection with a R0 resection rate of 95%. pCR (ypT0N0) was observed in 3 patients (15.8%). 2 patients (10.5%) achieved complete remission of the primary tumor (ypT0N1). 1 patient (5.3%) had an American Society of Pathologists (CAP) score of 1, 7 patients (36.8%) had a CAP score of 2, and 8 patients (6/19, 31.6%) had a CAP score of 3. Most treatment-related AEs (TRAEs) were grade 1 or 2. 8 cases (30.8%), 13 cases (50%), and 1 case (3.8%) developed leukopenia, decreased neutrophil count, and dermatitis, respectively ¾ Level TRAE. In terms of surgical complications, 2 patients had anastomotic leakage (10%), and 1 patient had recurrent laryngeal nerve injury (5%).
Conclusions
The combination of neoadjuvant Durvalumab chemotherapy has achieved satisfactory initial efficacy and safety results in locally advanced ESCC. Neoadjuvant immunotherapy does not increase perioperative complications and can achieve higher pathological remission rates, which may lead to better PFS and OS in the future. This study is currently the first clinical trial to use PD-L1 inhibitors in the treatment of esophageal squamous cell carcinoma.
Clinical trial identification
NCT04568200.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract